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Background. Shiga toxin–producing Escherichia coli (STEC) infections are leading causes of pediatric acute renal failure. 
Identifying hemolytic uremic syndrome (HUS) risk factors is needed to guide care.
Methods. We conducted a multicenter, historical cohort study to identify features associated with development of HUS (pri-
mary outcome) and need for renal replacement therapy (RRT) (secondary outcome) in STEC-infected children without HUS at 
initial presentation. Children aged <18 years who submitted STEC-positive specimens between January 2011 and December 2015 at 
a participating study institution were eligible.
Results. Of 927 STEC-infected children, 41 (4.4%) had HUS at presentation; of the remaining 886, 126 (14.2%) developed 
HUS. Predictors (all shown as odds ratio [OR] with 95% confidence interval [CI]) of HUS included younger age (0.77 [.69–.85] per 
year), leukocyte count ≥13.0 × 103/μL (2.54 [1.42–4.54]), higher hematocrit (1.83 [1.21–2.77] per 5% increase) and serum creatinine 
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per 1 mmol/L decrease), and intravenous fluid administration initiated ≥4 days following diarrhea onset (2.50 [1.14–5.46]). A longer 
interval from diarrhea onset to index visit was associated with reduced HUS risk (OR, 0.70 [95% CI, .54–.90]). RRT predictors (all 
shown as OR [95% CI]) included female sex (2.27 [1.14–4.50]), younger age (0.83 [.74–.92] per year), lower serum sodium (1.15 
[1.04–1.27] per mmol/L decrease), higher leukocyte count ≥13.0 × 103/μL (2.35 [1.17–4.72]) and creatinine (7.75 [1.20–50.16] per 
1 mg/dL increase) concentrations, and initial intravenous fluid administration ≥4 days following diarrhea onset (2.71 [1.18–6.21]).
Conclusions. The complex nature of STEC infection renders predicting its course a challenge. Risk factors we identified high-
light the importance of avoiding dehydration and performing close clinical and laboratory monitoring.
Keywords. Shiga-toxigenic Escherichia coli; hemolytic uremic syndrome; renal replacement therapy; emergency service; child.
Acute bloody diarrhea is a medical emergency that commonly 
prompts visits to emergency departments (EDs) and is present 
in up to 15% of children with diarrhea who seek ED care [1]. 
Shiga toxin–producing Escherichia coli (STEC) and, in partic-
ular, E. coli O157:H7 [2] are the most concerning pathogens in 
this scenario, because of their ability to cause hemolytic uremic 
syndrome (HUS), which consists of nonimmune hemolytic 
anemia, thrombocytopenia, and azotemia [3]. The risk of poor 
outcomes in STEC infections is not trivial: E. coli O157:H7, the 
most frequently recovered STEC in EDs [4], causes HUS in ap-
proximately 15% of infected children <10 years of age [5].
STEC-infected children frequently present to North 
American EDs [6]. On this first visit, critical decisions might 
influence disease course, which evolves over several days to 
either HUS or spontaneous resolution. Individual physicians 
rarely develop experiential knowledge about these uncommon 
infections and must rely on published evidence. Some risk 
factors for the development of HUS [5, 7, 8] and need for renal 
replacement therapy (RRT) among those who already have 
HUS [9–11] have been identified. However, the paucity of 
studies relating early illness characteristics to these outcomes 
perpetuates the assumption that little can be done to change di-
sease course [12]. Here, we present a multicenter, multinational, 
ED-based, historical cohort study of STEC-infected children to 
identify modifiers of disease severity.
METHODS
Study Design and Setting
Thirty-eight tertiary care pediatric EDs in 21 US states and 6 
Canadian provinces participated (Supplementary Table 1). 
The protocol was endorsed by Pediatric Emergency Research 
Canada (https://perc-canada.ca/) [13] and the Pediatric 
Emergency Medicine Collaborative Research Committee 
(PEMCRC; http://pemcrc.pemfellows.com/). All sites obtained 
institutional review board approval of waiver of informed con-
sent and data-sharing agreements with the coordinating institu-
tion and the PEMCRC data center (Baylor School of Medicine).
Study Population
We queried each institution’s microbiology databases to iden-
tify all children <18  years of age who had STEC detected in 
their stools between 1 January 2011 and 31 December 2015. 
Microbiologic testing included screening specimens on chro-
mogenic and selective agar with serologic confirmation of 
candidate colonies, polymerase chain reaction directly on 
specimens or after overnight growth, and/or Shiga toxin de-
tection on broth culture of stool by enzyme immunoassay 
and varied by institution and over time. We analyzed records 
of STEC-positive patients who visited the study institution 
ED and reviewed the records of children who returned up to 
30 days later. Children admitted directly to inpatient units were 
excluded because of incomplete prehospital data.
Data Sources, Collection, and Extraction
After standardized training, site investigators reviewed and 
systematically entered medical data into a REDCap (Research 
Electronic Data Capture) database [14]. The manual of opera-
tions detailed all data extraction procedures.
Objectives and Outcome Measures
Our primary and secondary objectives were to identify inde-
pendent risk factors for development of HUS among STEC-
infected children who did not have HUS at the index visit, and 
for use of RRT if and when HUS developed [15, 16]. We also 
sought to quantify the frequency of other interventions and 
complications and to identify clinically relevant cut-points for 
laboratory variables that might predict HUS: serum sodium, lac-
tate dehydrogenase (LDH) [17] and creatinine concentrations, 
platelet and peripheral white blood cell (WBC) counts [18], and 
hematocrit [11].
Definitions
Employing a validated case definition [19], we classified 
participants as having HUS if each the following was present 
[5]: hematocrit ≤30%, platelet count ≤150 × 103/μL, and serum 
creatinine concentration above the upper limit of normal for age 
[20]. We defined RRT as hemodialysis (including continuous 
veno-veno hemodialysis) or peritoneal dialysis. We recorded 
as present or absent neurologic (ie, seizures, stroke, coma), 
respiratory (ie, pulmonary edema, acute respiratory distress 
syndrome), gastrointestinal (ie, pancreatitis, intussusception, 
laparotomy, bowel resection), cardiovascular (ie, arrhythmias, 
myocardial depression), and/or infectious (ie, bacteremia, per-
itonitis, urinary tract infection, abscess) complications and 
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and/or platelet transfusions, therapeutic plasma exchange, 
eculizumab infusion, endotracheal intubation, central line in-
sertion, and intensive care unit (ICU) admission.
We defined the index ED visit as the first visit to the 
participating site related to the STEC infection. We defined 
the first days of illness and of HUS as the first calendar day of 
diarrhea and the calendar day on which all laboratory criteria 
for HUS were met, respectively [21]. We categorized intrave-
nous fluid (IVF) administration in the ED as yes/no. We also 
calculated the interval from the first day of diarrhea to the first 
IVF administration, and based on earlier work, a priori di-
chotomously evaluated initial IVF administration as occurring 
before vs on or after day 4 of illness [21, 22]. We considered 
nondocumentation of antibiotic administration, fever, dark 
urine, diarrhea, bloody diarrhea, vomiting, swelling/edema, 
delayed capillary refill, jaundice, bruising or petechiae, crackles 
on auscultation, and abdominal tenderness to imply “not pre-
sent” [23, 24]. We employed explicit terminology to classify 
participants as ill-appearing, dehydrated, or in respiratory dis-
tress [25]. We defined anuria as absence of urine output for >12 
hours [26].
Statistical Analysis
For the primary outcome, we compared characteristics of those 
who developed HUS with those who did not. Categorical and 
continuous variables were compared between groups using χ2 
and Mann-Whitney U tests, respectively. Confidence intervals 
(CIs) around frequencies were determined using the binomial 
exact method. Median differences of WBC and platelet counts, 
hematocrit values, and serum creatinine, sodium, and LDH 
concentrations were computed with the Hodges-Lehmann es-
timate based on the Wilcoxon rank-sum test of the difference 
between medians.
For regression models, we used complete case analysis. We 
initially performed a mixed-effect, multilevel logistic regression 
to account for clustering by center with study site as the random-
effect intercept, but the negligible intracluster correlation coef-
ficient (0.04 for HUS; 0.05 for RRT) implied minimal grouping 
effect. Therefore, we used logistic regression to estimate inde-
pendent associations between HUS and a priori hypothesized 
risk factors: age, sex, presence of vomiting, hematochezia, de-
hydration, antibiotic administration before HUS diagnosis, 
index ED visit hematocrit, WBC and platelet count, serum cre-
atinine and sodium, and duration of diarrhea before the first 
ED visit and to IVF administration. Covariates were tested for 
co-linearity. If present, the covariate with the greatest signifi-
cance in the original model was retained. We included WBC 
and platelet counts as dichotomous covariates employing 13.0 × 
103/μL and 250 × 103/μL as cut-points, respectively. LDH was 
not included in the model because it was relatively infrequently 
performed. We used the –2 log likelihood statistic and the 
Hosmer-Lemeshow test to evaluate the goodness of fit.
RRT use was analyzed as described for the primary outcome. 
STEC-associated complications were summarized using counts 
and percentages with 95% CIs. For laboratory parameter cut-
points, we plotted receiver operating characteristic curves with 
HUS outcome status, and we used the Youden index and dis-
tance to corner values on the curve to identify cutoffs.
A 2-sided α of .05 was used. To control for false discovery, 
we corrected P values using the Benjamini-Hochberg method 
within test sets [27]. Data were analyzed using SPSS version 
24.0 for Windows (SPSS Inc, Chicago, Illinois) and Stata version 
15.0 (StataCorp, College Station, Texas) software.
RESULTS
Population, Testing, and STEC Serotype
Stool from 704 of 927 (75.9%) cases (Figure 1) underwent Shiga 
toxin testing and culture; 216 (23.3%) and 7 (0.8%) underwent 
only culture and Shiga toxin testing, respectively. Among the 
cultured stools, 79.9% (735/920) contained an STEC isolate, 
and 18.8% (173/920) and 1.3% (12/920) were culture negative 
or had no results available, respectively. Forty-one of 927 chil-
dren (4.4% [95% CI, 3.2%–6.0%]) presented with established 
HUS and were excluded from primary and secondary out-
come analyses. Escherichia coli O157:H7 accounted for 79.0% 
(132/167) of HUS cases (Supplementary Figure 1).
Hemolytic Uremic Syndrome
Hemolytic uremic syndrome developed in 126 of the 866 (14.2% 
[95% CI, 12.0%–16.7%]) children who did not have HUS at the 
index visit, after a median of 3 days (interquartile range [IQR], 
2–5 days); of these, 35 (27.8% [95% CI, 20.2%–36.5%]) returned 
with HUS after initial discharge. STEC-infected children who 
subsequently developed HUS were more likely to report fever, 
reduced oral intake and urine output, hematochezia, vomiting, 
and abdominal pain and were younger, more likely to appear ill, 
considered to be dehydrated, and to have received antibiotics 
than those who did not (Table 1). Patients who developed HUS 
after the index ED visit also had higher first-visit median WBC 
counts (14.8 vs 10.6 × 103/μL; difference, 4.4 [95% CI, 3.4–5.5]) 
and serum LDH concentrations (802 vs 242 U/L; difference, 
525 [95% CI, 109–2306]) compared with those who did not 
(Table 2; Figure 2).
Covariates independently associated with HUS in regression 
analysis (Table 3) included younger age (odds ratio [OR], 0.77 
[95% CI, .69–.85] per year increase), higher hematocrit (OR, 
1.83 [95% CI, 1.21–2.77] per 5% increase), WBC count ≥13.0 × 
103/μL (OR, 2.54 [95% CI, 1.42–4.54]), and platelet count 
<250 × 103/μL (OR, 1.92 [95% CI, 1.02–3.60]). IVF started on 
or after day 4 of diarrhea compared to those who received no 
IVF or for whom it was administered before day 4 of diarrhea 
was associated with an increased risk of HUS (OR, 2.50 [95% 
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diarrhea onset, the less likely they were to develop HUS (OR, 
0.70 [95% CI, .54–.90]). Other covariates independently associ-
ated with increased HUS risk included higher serum creatinine 
and lower serum sodium values.
Renal Replacement Therapy
Ninety-four of 927 (10.1% [95% CI, 8.3%–12.3%]) children un-
derwent RRT, including 74 of 886 (8.4% [95% CI, 6.7% 10.4%]) 
without HUS at initial presentation. Of the latter group of 74 
children, 15 (20.3% [95% CI, 12.2%–31.5%]) were discharged 
to home following the index ED visit. RRT was independently 
associated with female sex (OR, 2.27 [95% CI, 1.14–4.50]), 
younger age (OR, 0.83 [95% CI, .74–.92] per year increase), 
and noninitiation of IVFs before day 4 of diarrhea (OR, 2.71 
[95% CI, 1.18–6.21]) compared with those who did not receive 
IVF or for whom it was administered before this point in ill-
ness (Table 3). Other covariates independently associated with 
RRT use included higher WBC count and serum creatinine and 
lower serum sodium concentrations.
Complications
Complications are shown in Supplementary Table 2. Of the 167 
participants with HUS, 32 (19.2%) were admitted to the ICU 
from the ED including 26 (15.6%) who required mechanical 
ventilation. In addition, 144 (86.2%) children received erythro-
cyte transfusions and 50 (29.9%) received platelet transfusions. 
Two children (1.2%) with HUS died during hospital admission. 
Eight of the 9 children who received eculizumab required RRT, 
and 1 of these died. Complications were uncommon among 
children without HUS. There was no difference between sites 
in the provision rates of antibiotics or IVFs in participants with 
STEC infection, or in the provision rates of RRT in participants 
who developed HUS (Supplementary Tables 1, 3, and 4).
Laboratory Parameters
In the bivariate analyses, only WBC and LDH concentration 
predicted HUS development. The optimal index ED visit cut-
points to predict development of HUS were 13.0 × 103/μL and 
275 U/L for WBC count and LDH concentration, respectively. 
These values had the following sensitivities and specificities: 
63.9% (95% CI, 54.0%–72.8%) and 71.9% (95% CI, 67.6%–
75.8%), respectively, for WBC count, and 77.8% (95% CI, 
51.9%–92.6%) and 63.4% (95% CI, 46.9%–77.4%), respectively, 
for LDH (Supplementary Figure 2).
DISCUSSION
Our findings reinforce the notion that EDs are crucial venues 
for care of children at risk of developing HUS. Specifically, 1 in 
7 STEC-infected children without HUS at the index visit de-
veloped HUS within the next week. It is concerning that nearly 
30% of those who developed HUS did so after being discharged 
following their index ED evaluation, possibly because the lab-
oratory features of HUS (ie, anemia, thrombocytopenia, and 
azotemia) do not clearly identify those who will develop HUS. 
Notably, a disproportionate number of children in this re-
turning group required RRT when HUS ensued.
Our venue-based study confirmed several risk factors for 
development of HUS, including younger age [28, 29] and 
higher WBC count [5, 30]. Although prior work suggests that 
Figure 1. Flow diagram of study participants, including development of hemolytic uremic syndrome and emergency department disposition. Abbreviations: ED, emergency 
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Table 1. Clinical Characteristics of Subjects Without Hemolytic Uremic Syndrome at the Index Emergency Department Visit
Characteristic
No HUS Following the Index ED Visit  
(n = 760)
Developed HUS Following the Index ED Visit 
(n = 126)
P ValueaNo. With Data Available No. (%) No. With Data Available No. (%)
Categorical variables      
 Sex, female 760 349 (45.9) 126 70 (55.6) .05
 Month of index visit 760  126   
  January–March  83 (10.9)  14 (11.1) .69
  April–June  183 (24.1)  29 (23.0)  
  July–September  364 (47.9)  56 (44.4)  
  October–December  130 (17.1)  27 (21.4)  
 Travel outside US/Canada past 30 d (yes) 527 37 (7.0) 87 4 (4.6) .49
 NSAID use past 2 wk (yes) 228 52 (22.8) 42 9 (21.4) >.99
 Fever (yes) 760 259 (34.1) 125 63 (50.4) <.001
 Decreased urine output (yes) 464 119 (25.6) 90 45 (50.0) <.001
 Anuria (yes)b 412 7 (1.7) 73 9 (12.3) <.001
 Diarrhea (yes) 760 739 (97.2) 125 123 (98.4) .56
 Hematochezia (yes) 759 576 (75.9) 125 107 (85.6) .02
 Vomiting (yes) 759 323 (42.6) 125 82 (65.6) <.001
 Abdominal pain (yes) 691 585 (84.7) 110 101 (91.8) .06
 Decreased oral fluid intake (yes) 553 317 (57.3) 105 78 (74.3) .002
 Ill appearance (yes)c 710 84 (11.8) 120 46 (38.3) <.001
 Dehydration (yes)d 682 164 (24.0) 117 49 (41.9) <.001
 Capillary refill time increased (yes) 760 44 (5.8) 125 17 (13.6) .003
 Abdominal tenderness (yes) 760 361 (47.5) 125 69 (55.2) .12
 Antibiotics used in past 2 wk (includes ED) 760 51 (6.7) 124 12 (9.7) .26
 IVF started before HUS diagnosed 747  125  <.001
  On day 1 of diarrhea  30 (4.0)  11 (8.8)  
  On day 2 of diarrhea  84 (11.2)  23 (18.4)  
  On day 3 of diarrhea  128 (17.1)  28 (22.4)  
  On or after day 4 of diarrhea  223 (29.9)  63 (50.4)  
  No IVF  282 (37.8)  0 (0)  
Continuous variables No. in Analysis Median (IQR) No. in Analysis Median (IQR)  
 Age, mo 760 79.5 (35.6–141.3) 126 56.8 (33.0–91.0) <.001
 Weight, kg 751 21.8 (14.2–41.0) 126 17.8 (13.4–25.1) <.001
 Days of illness at presentation 741 2.9 (1.9–4.4) 125 2.8 (1.6–3.6) .02
 Days of bloody diarrhea at presentation 565 1.2 (0.6–1.9) 113 0.9 (0.5–1.8) .14
 Days of diarrhea at presentation 738 2.9 (1.9–4.4) 125 2.8 (1.6–3.6) .01
 Maximum temperature in ED, °C 722 37.0 (36.7–37.3) 121 37.1 (36.8–37.5) .03
 Systolic blood pressure, mm Hg 672 113 (103–123) 116 112 (103–122) .63
 Diastolic blood pressure, mm Hg 668 70 (62–78) 115 73 (65–80) .02
 Heart rate, beats/minute, age group      
  <1.0 y 40 132 (120–140) 2 131 (127–131) .89
  1.0 to <2.0 y 81 130 (113–140) 20 132 (120–150) .13
  2.0 to <5.0 y 183 115 (101–125) 46 124 (112–140) .002
  5.0 to <11.0 y 228 97 (86–112) 47 112 (96–125) <.001
  11.0 to <18.0 y 220 88 (78–100) 11 99 (72–110) .67
 Respiratory rate, breaths/min, age group      
  <1.0 y 40 32 (28–38) 2 33 (28–33) .88
  1.0 to <2.0 y 79 28 (24–32) 20 29 (24–32) .60
  2.0 to <5.0 y 178 24 (22–26) 45 24 (23–28) .12
  5.0 to <11.0 y 227 20 (20–24) 47 22 (20–24) .007
  11.0 to <18.0 y 219 20 (18–20) 11 20 (18–20) .99
Abbreviations: ED, emergency department; HUS, hemolytic uremic syndrome; IQR, interquartile range; IVF, intravenous fluids; NSAID, nonsteroidal anti-inflammatory drug; US, United 
States.
aP < .03 was considered statistically significant with P value adjustment via Benjamini-Hochberg procedure for multiple comparisons (n = 36) [27].
bNo urine output for >12 hours.
cSick, toxic, shocky, decreased mental status, lethargic, unresponsive, irritable, fussy, inconsolable, not looking well, poor or decreased pulses, decreased pulses, or other similar terms.
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intravascular volume expansion early in illness is associated 
with better outcomes if HUS ensues [21, 22], we identified for 
the first time that intravenous volume expansion on or before 
day 4 of illness was associated with a lower risk of HUS. The 
value of volume expansion may be understated because chil-
dren who present early in illness have higher rates of HUS, 
reflecting a severe, fulminant course. This early-presenting 
group therefore presents a paradox: They are the patients 
most likely to experience HUS and require RRT, and simul-
taneously, their early presentation offers an opportunity to 
improve outcomes. Our work also identified several novel pre-
HUS variables relevant to HUS severity. Notably, lower serum 
sodium concentration and elevated serum creatinine at pre-
sentation and failure to administer IVF before day 4 of illness 
were associated with an increased risk of requiring RRT in 
those who develop HUS. These findings are important because 
dehydration and relative hyponatremia are potentially correct-
able or avoidable pre-HUS risk factors, and there is precedent 
for vigorous intravascular volume expansion among children 
with established HUS [31].
We note that initial presentation analyses such as ours should 
be interpreted in light of the kinetics of progression of STEC 
infections to HUS. Though a highly patterned sequence of 
events occurs in STEC-infected individuals, culminating in 
HUS vs uncomplicated resolution, trajectories of deteriora-
tion are quite variable. In prospective studies, the median day 
of meeting the criteria for HUS is 6.5–7.0. Although diagnostic 
criteria are rarely met before day 5 of illness [5, 32], a diagnosis 
of HUS can occur as late as day 13 [5, 21]. Our finding that the 
risk of HUS is lower in children with a greater interval between 
diarrhea onset and ED presentation, an association noted previ-
ously [33, 34], suggests that a rapidly progressive early in illness 
course is associated with worse outcome. In infected children, 
fecal and circulating Shiga toxin concentrations diminish rap-
idly and often disappear before HUS ensues [30, 35]. Hence, 
it is possible that the shorter the duration to presentation, the 
greater the vascular injury, and that later-presenting children 
may be experiencing a less accelerated course. The association 
between later-in-illness administration of IVF and HUS de-
velopment and need for RRT likely reflects the deteriorating 
clinical condition and the lack of IVF administration early in 
illness. These issues highlight the need for a prospective trial to 
evaluate the role of IVF early in illness.
Literature is sparse on the ability of serum LDH to predict 
HUS. As LDH is an enzyme expressed in erythrocytes, early 
intravascular hemolysis [36] might offer a pathophysiologic 
explanation for this finding. However, this variable was avail-
able for only 59 of the children, thereby precluding its inclu-
sion in the regression model. Urinalyses are too insensitive to 
use as a screening test. Interestingly, the bivariate association 
between occult blood in the urine and subsequent develop-
ment of HUS may reflect early hemolysis, which could also ex-
plain the elevated LDH concentrations seen at the index visit. 
Further studies should explore the utility of microhematuria 
Table 2. Laboratory Characteristics of Subjects Without Hemolytic Uremic Syndrome at the Index Emergency Department Visita
Characteristic
No HUS Following the Index ED Visit 
(n = 760)
Developed HUS Following the Index ED Visit 
(n = 126)
P Valueb No. Performed Median (IQR) No. Performed Median (IQR)
WBC count, ×103/μL 484 10.6 (8.7–13.2) 108 14.8 (11.8–21.0) <.001
Hemoglobin, g/dL 484 13.7 (12.6–14.7) 109 14.0 (12.6–15.0) .28
Hematocrit, % 483 39.7 (37.0–43.0) 109 40.7 (37.2–43.0) .25
Platelet count, ×103/μL 481 270 (230–329) 106 270 (207–332) .45
Lactate dehydrogenase, U/L 41 242 (190–293) 18 802 (282–4103) <.001
Serum sodium, mEq/L 454 138 (136–140) 103 136 (133–138) <.001
Serum bicarbonate, mEq/L 422 22 (20–24) 101 20.0 (18–23) <.001
Serum creatinine, mg/dL 455 0.4 (0.3–0.6) 102 0.4 (0.3–0.6) .71
Blood urea nitrogen, mg/dL 440 9.0 (7.0–12.0) 101 11.0 (8.0–14.3) <.001
Erythrocyte sedimentation rate, 
mm/h
124 10 (6–15) 21 8 (6–13) .22
C-reactive protein, mg/dL 174 2.0 (1.0–5.3) 35 5.6 (1.6–33.3) .002
Urine protein positive,c No. (%) 242 78 (32.2) 40 19 (47.5) .07
Urine protein ≥3+ (ie, large), No. (%) 76 8 (10.5) 17 3 (17.6) .68
Urine blood positived, No. (%) 231 83 (35.5) 40 16 (40.0) .60
Urine blood ≥3+ (ie, large), No. (%) 80 9 (11.3) 15 5 (33.3) .04
Data are presented as median (IQR) unless otherwise indicated.
Abbreviations: ED, emergency department; HUS, hemolytic uremic syndrome; IQR, interquartile range; WBC, white blood cell.
aTable excludes the 41 children who had HUS at the time of the index ED visit.
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and elevated LDH as early markers of hemolysis in patients 
infected with STEC. However, elevations should be interpreted 
cautiously, as many children who did not develop HUS had 
serum LDH concentrations above the upper limit of normal for 
age, and the day-to-day trajectories of the abnormalities we pre-
sent have not been established.
Our findings also highlight the possibility that the strict def-
inition of HUS, particularly the criteria of anemia, serves as 
an obstacle to the early diagnosis and management of HUS. 
During the pre-HUS phase, children suffering from diarrhea 
and vomiting are often dehydrated; consequently, the serum 
hemoglobin is disproportionately elevated relative to the in-
travascular red cell mass, yielding a value that prevents the 
establishment of a diagnosis of HUS. This discordance is omi-
nous, because it reflects severe relative hemoconcentration and 
a poor prognosis [37]. Serum LDH concentrations may serve 
to identify hemolysis prior to the development of anemia, and 
clinicians should consider such children as having HUS [37], 
thereby triggering more aggressive monitoring and potentially 
volume expansion [21, 22, 31].
We did not include precise microbial etiology as a risk factor, 
even though postdiarrheal HUS is almost exclusively caused 
by STEC that contain a gene encoding Shiga toxin 2, a geno-
type that includes almost all E. coli O157:H7 [38]. Increasingly, 
clinicians have rapid access to the pathogen’s genotype [39], and 
the presence of Shiga toxin 2 will be factored into HUS risk-
assessment paradigms. The availability of such etiologic clarity 
at the index ED visit will obviate concerns that our study limited 
risk assessment only to patients who were subsequently deter-
mined to be infected with STEC. This is important because we 
did not include in our analyses the larger population of children 
with bloody diarrhea caused by pathogens that have no risk 
of causing HUS, such as Campylobacter, salmonellae, or non-
dysenteriae shigellae.
A limitation to our study is its retrospective design, which 
resulted in missing data, especially day-by-day volume and con-
tent of IVF administered. Because data were likely not missing 
at random, we did not employ multiple imputation to overcome 
potential biases introduced by incomplete data, as its use would 
have been inappropriate [40]. Additionally, not all sites produced 
Figure 2. Violin plots of white blood cell count, hematocrit, platelet, serum creatinine, serum sodium, and lactate dehydrogenase of children who did and those who did 
not develop HUS after the index emergency department visit. The white dot represents the median, the black vertical bar the interquartile range, the thin vertical line the 
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useful data throughout the 5-year study period. Almost all sites 
were large tertiary care centers, so our data might not be gen-
eralizable to the larger community [41]. However, participating 
sites were from diverse geographic regions, and many serve 
rural and urban populations. Also, we have incomplete data on 
discharged patients who did not return to the index hospital 
within 30 days, but it is unlikely they would have gone to another 
institution if HUS developed, as participating study centers have 
pediatric nephrology expertise. Nonetheless, we cannot exclude 
the small possibility that we missed some cases of HUS, thereby 
underestimating its frequency.
In summary, HUS occurred in nearly 1 in 5 STEC-infected 
children, and 1 in 7 infected children without HUS at the index 
ED visit. In regression analysis, development of HUS was as-
sociated with higher serum creatinine and hematocrit values 
and lower platelet counts at presentation, and independent 
predictors included shorter symptom duration, younger age, 
higher WBC count, lower serum sodium, and IVF administra-
tion ≥4 days following diarrhea onset. Female sex, younger age, 
higher WBC count and serum creatinine, lower serum sodium, 
and administration of IVF ≥4 days following the onset of di-
arrhea predicted RRT. Large prospective studies are needed to 
assess if early intravascular volume expansion and correction of 
dysnatremia mitigate disease progression.
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